Barclays’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-571,990
| Closed | -$3.34M | – | 5518 |
|
|
2022
Q4 | $3.34M | Buy |
571,990
+119,236
| +26% | +$627K | ﹤0.01% | 1903 |
|
|
2022
Q3 | $3.03M | Buy |
452,754
+75,341
| +20% | +$457K | ﹤0.01% | 1469 |
|
|
2022
Q2 | $1.59M | Buy |
377,413
+333,759
| +765% | +$1.32M | ﹤0.01% | 2014 |
|
|
2022
Q1 | $147K | Hold |
43,654
| – | – | ﹤0.01% | 3605 |
|
|
2021
Q4 | $138K | Sell |
43,654
-3,826
| -8% | -$12.7K | ﹤0.01% | 3662 |
|
|
2021
Q3 | $156K | Buy |
47,480
+445
| +0.9% | +$1.56K | ﹤0.01% | 3736 |
|
|
2021
Q2 | $198K | Sell |
47,035
-21,365
| -31% | -$90.4K | ﹤0.01% | 3560 |
|
|
2021
Q1 | $341K | Buy |
68,400
+14,642
| +27% | +$118K | ﹤0.01% | 3429 |
|
|
2020
Q4 | $680K | Buy |
53,758
+33,925
| +171% | +$387K | ﹤0.01% | 3031 |
|
|
2020
Q3 | $195K | Buy |
19,833
+4,088
| +26% | +$40.3K | ﹤0.01% | 3877 |
|
|
2020
Q2 | $156K | Buy |
15,745
+7,043
| +81% | +$67.5K | ﹤0.01% | 4248 |
|
|
2020
Q1 | $76K | Sell |
8,702
-13,405
| -61% | -$132K | ﹤0.01% | 4975 |
|
|
2019
Q4 | $204K | Buy |
22,107
+10,653
| +93% | +$75.5K | ﹤0.01% | 5014 |
|
|
2019
Q3 | $67K | Sell |
11,454
-5,431
| -32% | -$57.6K | ﹤0.01% | 5758 |
|
|
2019
Q2 | $203K | Sell |
16,885
-69,149
| -80% | -$744K | ﹤0.01% | 5092 |
|
|
2019
Q1 | $1.04M | Buy |
86,034
+84,114
| +4,381% | +$1.24M | ﹤0.01% | 3359 |
|
|
2018
Q4 | $25K | Sell |
1,920
-18,030
| -90% | -$249K | ﹤0.01% | 5803 |
|
|
2018
Q3 | $297K | Buy |
19,950
+12,334
| +162% | +$194K | ﹤0.01% | 4692 |
|
|
2018
Q2 | $129K | Sell |
7,616
-647
| -8% | -$12.6K | ﹤0.01% | 5072 |
|
|
2018
Q1 | $189K | Sell |
8,263
-12,419
| -60% | -$276K | ﹤0.01% | 4872 |
|
|
2017
Q4 | $534K | Buy |
20,682
+12,700
| +159% | +$256K | ﹤0.01% | 3764 |
|
|
2017
Q3 | $118K | Buy |
7,982
+7,673
| +2,483% | +$111K | ﹤0.01% | 4816 |
|
|
2017
Q2 | $4K | Sell |
309
-4,238
| -93% | -$62.5K | ﹤0.01% | 6314 |
|
|
2017
Q1 | $78K | Buy |
4,547
+65
| +1% | +$780 | ﹤0.01% | 5066 |
|
|
2016
Q4 | $46K | Buy |
4,482
+4,165
| +1,314% | +$38.1K | ﹤0.01% | 5220 |
|
|
2016
Q3 | $3K | Sell |
317
-48
| -13% | -$524 | ﹤0.01% | 6171 |
|
|
2016
Q2 | $4K | Buy |
365
+231
| +172% | +$2.94K | ﹤0.01% | 5815 |
|
|
2016
Q1 | $1K | Sell |
134
-440
| -77% | -$6.33K | ﹤0.01% | 6035 |
|
|
2015
Q4 | $10K | Sell |
574
-5,973
| -91% | -$130K | ﹤0.01% | 5412 |
|
|
2015
Q3 | $117K | Buy |
6,547
+6,159
| +1,587% | +$105K | ﹤0.01% | 4516 |
|
|
2015
Q2 | $5K | Buy |
388
+238
| +159% | +$3.63K | ﹤0.01% | 6483 |
|
|
2015
Q1 | $2K | Buy |
+150
| New | +$2.09K | ﹤0.01% | 6904 |
|
|
2014
Q4 | – | Sell |
-72
| Closed | -$1K | – | 7694 |
|
|
2014
Q3 | $1K | Sell |
72
-20,441
| -100% | -$198K | ﹤0.01% | 7546 |
|
|
2014
Q2 | $205K | Buy |
20,513
+14,542
| +244% | +$140K | ﹤0.01% | 4794 |
|
|
2014
Q1 | $77K | Buy |
+5,971
| New | +$84.3K | ﹤0.01% | 5661 |
|
Barclays's CNCE Position: Q1 2023 in Review
Barclays sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 571,990 shares — an estimated $3.34M sold.
Barclays first reported a position in CNCE in Q1 2014 and held it in 35 quarters. The position peaked at $3.34M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Barclays reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Barclays sold 571,990 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.34M.
- Barclays first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 35 quarters.
- Barclays's Concert Pharmaceuticals, Inc. position peaked at $3.34M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.